Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Subcutaneous Panniculitis-Like T-Cell Lymphoma

Tundra lists 4 Subcutaneous Panniculitis-Like T-Cell Lymphoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT05475925

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-05

13 states

LGLL - Large Granular Lymphocytic Leukemia
Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma
+10
ACTIVE NOT RECRUITING

NCT01787409

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

Gender: All

Ages: 18 Years - Any

Updated: 2025-12-30

5 states

Aggressive Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-Cell Lymphoma
+12
ACTIVE NOT RECRUITING

NCT03598998

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-26

3 states

Anaplastic Large Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Recurrent Anaplastic Large Cell Lymphoma
+17
RECRUITING

NCT05978141

A Registry for People With T-cell Lymphoma

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Gender: All

Updated: 2025-05-21

15 states

T-cell Lymphoma
NK-Cell Lymphoma
T-cell Prolymphocytic Leukemia
+28